Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wefel, Jeffrey S., Cloughesy, Timothy, Zazzali, James L., Zheng, Maoxia, Prados, Michael, Wen, Patrick Y., Mikkelsen, Tom, Schiff, David, Abrey, Lauren E., Yung, W.K. Alfred, Paleologos, Nina, Nicholas, Martin K., Jensen, Randy, Vredenburgh, James, Das, Asha, Friedman, Henry S.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2011
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107095/
https://ncbi.nlm.nih.gov/pubmed/21558074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor024
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items